科研之友
微信
新浪微博
Facebook
分享链接
摘要
Blockade of the CTLA-4 and PD-1 inhibitory pathways in T cells via the administration of neutralizing antibodies at the time of interleukin (IL)-15 therapy markedly enhanced the survival of tumor-bearing mice as compared with those receiving IL-15 alone or IL-15 in combination with just one of the antibodies. Clin Cancer Res; 16(24); 5917-9.
- 出版日期2010-12-15
